---
layout: default
title: Lornoxicam
description: "Lornoxicam 的老藥新用潛力分析。中等證據等級 L3，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 中證據等級 (L3-L4)
nav_order: 99
evidence_level: L3
indication_count: 10
---

# Lornoxicam

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L3</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lornoxicam (勞諾昔康) - 藥師筆記

## 一句話總結

<p class="key-answer" data-question="Lornoxicam 可以用於治療什麼新適應症？">
Lornoxicam 為 oxicam 類 NSAID 止痛消炎藥，TxGNN 預測其可用於類風濕性關節炎及偏頭痛，兩項預測皆有豐富的 PubMed 文獻支持，偏頭痛更有 Phase 2 臨床試驗證據，證據等級達 L2-L3。
</p>


---

## 快速總覽

| 項目 | 內容 |
|------|------|
| 藥物名稱 | Lornoxicam (勞諾昔康) |
| DrugBank ID | DB06725 |
| 台灣商品名 | 療紓疼速效膜衣錠 |
| 原核准適應症 | 輕度至中度急性疼痛之短期止痛、退化性關節炎症狀緩解 |
| 預測新適應症 | rheumatoid arthritis、migraine with or without aura, susceptibility to、migraine disorder、migraine with brainstem aura、brachydactyly-syndactyly syndrome、colobomatous microphthalmia-rhizomelic dysplasia syndrome、headache disorder、trigeminal autonomic cephalalgia、tendinitis、idiopathic granulomatous myositis |
| TxGNN 預測分數 | 0.999 (RA)、0.999 (偏頭痛) |
| 證據等級 | **L2** (偏頭痛 - Phase 2 臨床試驗)、**L3** (類風濕性關節炎 - 多篇文獻) |
| 臨床試驗 | 有 (偏頭痛) |
| PubMed 文獻 | 豐富 (20+ 篇相關文獻) |

---






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. rheumatoid arthritis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.90%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>### 機轉推論</p>

<ol>
<li><strong>COX-1/COX-2 雙重抑制</strong>：Lornoxicam 是非選擇性 COX 抑制劑，可有效抑制前列腺素合成，減少發炎反應與疼痛。</li>

<li><strong>類風濕性關節炎應用</strong>：</li>
</ol>
<ul>
<li>NSAIDs 是類風濕性關節炎症狀控制的基礎用藥</li>
<li>Lornoxicam 的抗發炎與止痛效果適用於關節炎疼痛管理</li>
<li>相較其他 oxicam 類藥物，其半衰期較短 (3-5 小時)，可能減少副作用累積</li>

</ul>
<ol>
<li><strong>偏頭痛應用</strong>：</li>
</ol>
<ul>
<li>前列腺素在偏頭痛發病機轉中扮演重要角色</li>
<li>NSAIDs 已被證實可有效緩解偏頭痛急性發作</li>
<li>Lornoxicam 的快速起效特性適合急性偏頭痛治療</li>
</ul>

<h3>臨床試驗</h3>

<p>目前無針對此特定適應症的臨床試驗登記。</p>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27042335/" target="_blank">27042335</a></td><td>2016</td><td>Article</td><td>RMD open</td><td>Glucocorticoids and chronotherapy in rheumatoid arthritis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22469263/" target="_blank">22469263</a></td><td>2011</td><td>Article</td><td>Profiles of drug substances, e</td><td>Lornoxicam.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25553695/" target="_blank">25553695</a></td><td>2015</td><td>Article</td><td>Pakistan journal of pharmaceut</td><td>Formulation and evaluation of mini-tablets-filled-pulsincap delivery of lornoxic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32792844/" target="_blank">32792844</a></td><td>2020</td><td>Article</td><td>Saudi pharmaceutical journal :</td><td>Formulation and characterization of lornoxicam-loaded cellulosic-microsponge gel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29026298/" target="_blank">29026298</a></td><td>2017</td><td>Article</td><td>International journal of nanom</td><td>Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental mo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29056774/" target="_blank">29056774</a></td><td>2017</td><td>Article</td><td>Reumatologia</td><td>Glucocorticoid management in rheumatoid arthritis: morning or night low dose?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23567043/" target="_blank">23567043</a></td><td>2013</td><td>Article</td><td>Journal of controlled release </td><td>Intra-articular drug delivery from an optimized topical patch containing teriflu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39069701/" target="_blank">39069701</a></td><td>2024</td><td>Article</td><td>Anti-inflammatory &amp; anti-aller</td><td>Formulation and Characterization of Emulgel Lornoxicam Containing Lemon Grass Oi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8706598/" target="_blank">8706598</a></td><td>1996</td><td>Article</td><td>Drugs</td><td>Lornoxicam. A review of its pharmacology and therapeutic potential in the manage...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24967065/" target="_blank">24967065</a></td><td>2014</td><td>Article</td><td>Iranian journal of basic medic</td><td>Matrix-mini-tablets of lornoxicam for targeting early morning peak symptoms of r...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38953843/" target="_blank">38953843</a></td><td>2024</td><td>Article</td><td>Nanomedicine (London, England)</td><td>Optimizing lornoxicam-loaded poly(lactic-co-glycolic acid) and (polyethylene gly...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12207202/" target="_blank">12207202</a></td><td>2002</td><td>Article</td><td>Minerva medica</td><td>[Long term study on the efficacy and safety of lornoxicam in rheumatoid arthriti...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26556001/" target="_blank">26556001</a></td><td>2013</td><td>Article</td><td>Journal of pharmaceutics</td><td>Development and Evaluation of Dual Cross-Linked Pulsatile Beads for Chronotherap...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28283842/" target="_blank">28283842</a></td><td>2017</td><td>Article</td><td>Drug delivery and translationa</td><td>A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27086708/" target="_blank">27086708</a></td><td>2016</td><td>Article</td><td>Pain management</td><td>Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28711030/" target="_blank">28711030</a></td><td>2017</td><td>Article</td><td>International immunopharmacolo</td><td>Carvedilol can attenuate histamine-induced paw edema and formaldehyde-induced ar...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12404032/" target="_blank">12404032</a></td><td>2002</td><td>Article</td><td>Reumatismo</td><td>[Analgesic dose range finding of lornoxicam compared to diclofenac. Crossover do...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18479176/" target="_blank">18479176</a></td><td>2008</td><td>Article</td><td>Clinical drug investigation</td><td>Comparative bioavailability of lornoxicam as single doses of quick-release table...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12240779/" target="_blank">12240779</a></td><td>2002</td><td>Article</td><td>Clinical therapeutics</td><td>Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19821419/" target="_blank">19821419</a></td><td>2009</td><td>Article</td><td>The Cochrane database of syste</td><td>Single dose oral lornoxicam for acute postoperative pain in adults.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. migraine with or without aura, susceptibility to</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.87%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22938964/" target="_blank">22938964</a></td><td>2012</td><td>Article</td><td>Handbook of clinical neurology</td><td>Animal models.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16201993/" target="_blank">16201993</a></td><td>2005</td><td>Article</td><td>Epilepsia</td><td>Rearranging receptors.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22266888/" target="_blank">22266888</a></td><td>2011</td><td>Article</td><td>Seminars in neurology</td><td>Genetics of epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34575901/" target="_blank">34575901</a></td><td>2021</td><td>Article</td><td>International journal of molec</td><td>Selected Molecular Targets for Antiepileptogenesis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34209535/" target="_blank">34209535</a></td><td>2021</td><td>Article</td><td>International journal of molec</td><td>Neuroinflammation: A Signature or a Cause of Epilepsy?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17460155/" target="_blank">17460155</a></td><td>2007</td><td>Article</td><td>Neurology</td><td>Familial occipitotemporal lobe epilepsy and migraine with visual aura: linkage t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30267335/" target="_blank">30267335</a></td><td>2018</td><td>Article</td><td>Neurological sciences : offici</td><td>Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to epi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23294289/" target="_blank">23294289</a></td><td>2013</td><td>Article</td><td>Epilepsia</td><td>Evidence for a shared genetic susceptibility to migraine and epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32639997/" target="_blank">32639997</a></td><td>2020</td><td>Article</td><td>PLoS neglected tropical diseas</td><td>Protection or susceptibility to devastating childhood epilepsy: Nodding Syndrome...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28086980/" target="_blank">28086980</a></td><td>2017</td><td>Article</td><td>Journal of neuroinflammation</td><td>Inflammation in epileptogenesis after traumatic brain injury.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33856647/" target="_blank">33856647</a></td><td>2021</td><td>Article</td><td>Molecular neurobiology</td><td>Epilepsy and Migraine Shared Genetic and Molecular Mechanisms: Focus on Therapeu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19935934/" target="_blank">19935934</a></td><td>2009</td><td>Article</td><td>Tidsskrift for den Norske laeg</td><td>[Psychogenic non-epileptic seizures].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24874544/" target="_blank">24874544</a></td><td>2014</td><td>Article</td><td>Neurobiology of disease</td><td>Does gender influence susceptibility and consequences of acquired epilepsies?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28837072/" target="_blank">28837072</a></td><td>2017</td><td>Article</td><td>International journal of molec</td><td>Understanding the Epilepsy in POLG Related Disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16377142/" target="_blank">16377142</a></td><td>2006</td><td>Article</td><td>Epilepsy research</td><td>Pediatric epilepsy models.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32521797/" target="_blank">32521797</a></td><td>2020</td><td>Article</td><td>International journal of molec</td><td>Reactive Glia Inflammatory Signaling Pathways and Epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24643875/" target="_blank">24643875</a></td><td>2015</td><td>Article</td><td>Metabolic brain disease</td><td>Does abnormal glycogen structure contribute to increased susceptibility to seizu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21919606/" target="_blank">21919606</a></td><td>2011</td><td>Article</td><td>Pharmacogenomics</td><td>Pharmacogenomics of the human µ-opioid receptor.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12183340/" target="_blank">12183340</a></td><td>2002</td><td>Article</td><td>Brain : a journal of neurology</td><td>Disease modification in partial epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33187755/" target="_blank">33187755</a></td><td>2021</td><td>Article</td><td>Clinical neurology and neurosu</td><td>Association of KCNJ10 variants and the susceptibility to clinical epilepsy.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. migraine disorder</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.87%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00293657" target="_blank">NCT00293657</a></td><td>PHASE2</td><td>COMPLETED</td><td>150</td><td>A Randomized, Double-Blind, Single-Dose Study, Placebo-Controlled Evaluation of ...</td></tr>
</tbody>
</table>

<h3>相關文獻（2 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8706598/" target="_blank">8706598</a></td><td>1996</td><td>Article</td><td>Drugs</td><td>Lornoxicam. A review of its pharmacology and therapeutic potential in the manage...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1495823/" target="_blank">1495823</a></td><td>1992</td><td>Article</td><td>Pathologie-biologie</td><td>[Migraine and non-steroidal anti-inflammatory agents].</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. migraine with brainstem aura</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. brachydactyly-syndactyly syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. colobomatous microphthalmia-rhizomelic dysplasia syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.81%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. headache disorder</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00293657" target="_blank">NCT00293657</a></td><td>PHASE2</td><td>COMPLETED</td><td>150</td><td>A Randomized, Double-Blind, Single-Dose Study, Placebo-Controlled Evaluation of ...</td></tr>
</tbody>
</table>

<h3>相關文獻（2 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8706598/" target="_blank">8706598</a></td><td>1996</td><td>Article</td><td>Drugs</td><td>Lornoxicam. A review of its pharmacology and therapeutic potential in the manage...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1495823/" target="_blank">1495823</a></td><td>1992</td><td>Article</td><td>Pathologie-biologie</td><td>[Migraine and non-steroidal anti-inflammatory agents].</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. trigeminal autonomic cephalalgia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.75%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. tendinitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.72%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27468823/" target="_blank">27468823</a></td><td>2017</td><td>Article</td><td>Der Orthopade</td><td>Lornoxicam injection is inferior to betamethasone in the treatment of subacromia...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. idiopathic granulomatous myositis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.70%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

### 許可證狀態

| 許可證字號 | 商品名 | 劑型 | 持證商 | 狀態 | 效期 |
|-----------|--------|------|--------|------|------|
| (需確認) | 療紓疼速效膜衣錠 8 毫克 | 膜衣錠 | (需確認) | (需確認) | (需確認) |

### 核准適應症

1. 輕度至中度急性疼痛之短期止痛
2. 退化性關節炎之症狀及徵象緩解

### 建議劑量

- 急性疼痛：8-16 mg/day，分 2-3 次服用
- 關節炎：8-12 mg/day

---

## 安全性考量

### 藥物交互作用 (DDI)

根據 DDInter 資料庫，Lornoxicam 與多種藥物有交互作用。因屬 NSAID 類，主要交互作用與其他 NSAIDs 類似。

### 一般注意事項

1. **腸胃道風險**：
   - 與所有 NSAIDs 相同，可能導致胃潰瘍、出血
   - 建議與食物併服或使用胃保護劑

2. **心血管風險**：
   - 可能增加心血管事件風險
   - 高心血管風險患者應謹慎使用

3. **腎功能影響**：
   - 可能影響腎血流，腎功能不全患者需調整劑量
   - 避免與其他腎毒性藥物併用

4. **出血風險**：
   - 抑制血小板功能
   - 與抗凝血劑併用需謹慎

### 禁忌症

- 對 NSAIDs 過敏者
- 活動性消化性潰瘍
- 嚴重心臟衰竭
- 嚴重肝腎功能不全
- 妊娠後期

### 特殊族群

- **孕婦**：妊娠前期可謹慎使用，後期禁用
- **哺乳婦女**：不建議使用
- **老年人**：應使用最低有效劑量
- **兒童**：安全性未確立

---

## 結論與下一步

### 藥師評估

| 評估項目 | 類風濕性關節炎 | 偏頭痛 |
|---------|--------------|--------|
| 預測可信度 | 高 | 高 |
| 機轉合理性 | 高 | 高 |
| 臨床證據強度 | 中 (多篇文獻) | 中-高 (Phase 2 試驗) |
| 證據等級 | L3 | L2 |
| 建議優先度 | 可考慮探索 | 建議優先追蹤 |

### 建議

1. **類風濕性關節炎**：
   - 雖然台灣未核准此適應症，但國際文獻支持其療效
   - 可作為症狀控制的選項，但非 DMARD，無法延緩疾病進程
   - 考慮向衛福部申請適應症擴展

2. **偏頭痛**：
   - Phase 2 臨床試驗提供直接證據支持
   - 建議關注是否有 Phase 3 試驗進行
   - 可考慮在適當情況下 off-label 使用

3. **時序治療應用**：
   - 緩釋劑型的時序治療概念值得關注
   - 針對類風濕性關節炎早晨僵硬症狀可能有獨特優勢

### 證據等級說明

- **L2 (偏頭痛)**：具有 Phase 2 臨床試驗直接證據
- **L3 (類風濕性關節炎)**：具有多篇觀察性研究與臨床文獻支持

---

*本筆記由 TxGNN 老藥新用預測系統生成，僅供研究參考，不構成醫療建議。*

*生成日期：2026-02-11*


---

## 相關藥物報告

- [Aluminum Hydroxide]({{ "/drugs/aluminum_hydroxide/" | relative_url }}) - 證據等級 L3
- [Inositol]({{ "/drugs/inositol/" | relative_url }}) - 證據等級 L3
- [Propantheline]({{ "/drugs/propantheline/" | relative_url }}) - 證據等級 L3
- [Alfacalcidol]({{ "/drugs/alfacalcidol/" | relative_url }}) - 證據等級 L3
- [Amcinonide]({{ "/drugs/amcinonide/" | relative_url }}) - 證據等級 L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Lornoxicam老藥新用驗證報告. https://twtxgnn.yao.care/drugs/lornoxicam/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_lornoxicam,
  title = {Lornoxicam老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/lornoxicam/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
